X T L Biopharmaceuticals reported $706K in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 585K 260K Sep/2025
Bioline Rx USD 831K 622K Sep/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
X T L Biopharmaceuticals USD 706K 50K Dec/2024